Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) EPS (Weighted Average and Diluted) (2020 - 2025)

Sangamo Therapeutics (SGMO) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.11 as the latest value for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 8.33% year-over-year to -$0.11; the TTM value through Dec 2025 reached -$0.44, up 16.98%, while the annual FY2025 figure was -$0.44, 10.2% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.11 in Q4 2025 for Sangamo Therapeutics, roughly flat from -$0.11 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.12 in Q1 2023 and bottomed at -$0.66 in Q2 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.25, with a median of -$0.28 recorded in 2022.
  • Year-over-year, EPS (Weighted Average and Diluted) tumbled 3200.0% in 2021 and then surged 140.0% in 2023.
  • Sangamo Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.25 in 2021, then fell by 28.0% to -$0.32 in 2022, then fell by 6.25% to -$0.34 in 2023, then soared by 64.71% to -$0.12 in 2024, then grew by 8.33% to -$0.11 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.11, -$0.11, and -$0.08 for Q4 2025, Q3 2025, and Q2 2025 respectively.